Clinical Trials Browser

Recurrence × Breast × 90 days × Clear all

NCT07062965 2026-04-16

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Phase 3 Recruiting

400 enrolled

Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT03315364 2026-04-01

OPTIMAL

Phase 2/3 Active not recruiting

549 enrolled

Breast

Breast Neoplasms, Recurrence

NCT05283330 2026-03-20

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Phase 1 Recruiting

48 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Glioblastoma, Neoplasm Metastasis, Prostatic Neoplasms, Recurrence, Colorectal Neoplasms

NCT05537740 2026-03-20

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

129 enrolled

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT07484763 2026-03-20

Predicting Recurrence in HR+/HER2- Early Breast Cancer

Not yet recruiting

500 enrolled

Breast

Breast Neoplasms, Recurrence

NCT07478705 2026-03-17

EINSTEIN-TNBC

Phase NA Not yet recruiting

30 enrolled

Breast

Recurrence, Triple Negative Breast Neoplasms

NCT03742245 2026-03-16

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Phase 1 Active not recruiting

28 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT06704659 2026-03-09

RAY-no-BAN

Phase NA Recruiting

60 enrolled

Breast

Breast Neoplasms, Recurrence

NCT07458204 2026-03-09

EPPIL

Phase 2 Not yet recruiting

760 enrolled

Breast

Recurrence, Triple Negative Breast Neoplasms

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

1,020 enrolled

Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT02926690 2026-02-25

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

Phase 1 Recruiting

70 enrolled

Breast

Breast Neoplasms, Recurrence, Triple Negative Breast Neoplasms

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2 Active not recruiting

333 enrolled

Breast

Breast Neoplasms, Recurrence

NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Phase 3 Not yet recruiting

400 enrolled

Breast

Breast Neoplasms, Recurrence

NCT04150042 2026-01-29

SHARON

Phase 1 Recruiting

24 enrolled

BreastGastrointestinal

Breast Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Recurrence

NCT05150691 2026-01-28

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

796 enrolled

BreastGastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma